In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
The Shanghai-based firm will test the gene therapy candidate in patients between 4 and 9 years old with Duchenne muscular dystrophy.
Their study showed that DCIS patients with pathogenic variants in BRCA1/2 and PALB2 had a higher risk of developing invasive breast cancer than those without.
The firm said it has received positive feedback from the FDA on the design of a Phase III trial of ELI-002 in KRAS-mutant pancreatic cancer.
HHS is asking the court to affirm its Office of Inspector General's finding that paying for fertility services would run ...
NEW YORK – BlossomHill Therapeutics on Wednesday said it has begun treating lung cancer patients with EGFR- or HER2-mutated tumors with its OMNI-EGFR inhibitor BH-30643 in a Phase I/II trial. The ...
NEW YORK – Axovia Therapeutics and Viralgen on Wednesday said they have entered into a partnership to advance development and manufacturing for AXV-101, a gene therapy designed to treat retinal ...
Doctors and patient advocates supporting pretreatment testing at times challenged FDA and other experts who aren't swayed by available evidence.
The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback